Sana Biotechnology

104 articles about Sana Biotechnology

• Sana Biotechnology Publishes Early Clinical Data Showing that SC291, a CD19-directed Allogeneic CAR T Therapy, Evades Immune Detection in Presence of Intact Immune System

  12/1/2023

  Sana Biotechnology, Inc. (NASDAQ: SANA) today announced the publication in Blood of an abstract providing initial clinical data from the first patient treated at the lowest dose in the ongoing ARDENT Phase 1 clinical trial with SC291, a hypoimmune (HIP)-modified allogeneic CD19-directed CAR T cell therapy.

• Sana Biotechnology to Present at November and December 2023 Investor Conferences

  11/21/2023

  Sana Biotechnology, Inc. today announced that it will webcast its presentations at two investor conferences in November and December.

• Uppsala University Hospital and Sana Biotechnology Announce Authorization of the First-in-Human Clinical Trial Application for a Primary Islet Cell Treatment for Patients with Type 1 Diabetes

  11/17/2023

  Sana Biotechnology, Inc. and Uppsala University Hospital in Sweden today announced the Swedish Medical Products Agency has authorized Uppsala University’s Clinical Trial Application (CTA) to initiate an investigator-sponsored, first-in-human study of UP421, an allogeneic, primary islet cell therapy engineered with Sana’s hypoimmune (HIP) technology, in patients with type 1 diabetes.

• Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-directed Allogeneic CAR T Therapy, for Patients with Lupus Nephritis, Extrarenal Lupus, and ANCA-associated Vasculitis

  11/9/2023

  Sana Biotechnology, Inc. (NASDAQ: SANA) today announced the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application to initiate a study of SC291 in patients with multiple B-cell mediated autoimmune diseases, including lupus nephritis, extrarenal lupus, and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.

• Sana Biotechnology Reports Third Quarter 2023 Financial Results and Business Updates

  11/8/2023

  Sana Biotechnology, Inc., a company focused on changing the possible for patients through engineered cells, reported financial results and business highlights for the third quarter 2023.

• Sana Biotechnology Announces Five Presentations at the 65th American Society of Hematology Annual Meeting

  11/2/2023

  Sana Biotechnology, Inc., a company focused on changing the possible for patients through engineered cells, announced that five abstracts will have poster presentations at the 65th American Society of Hematology Annual Meeting to be held December 9-12, 2023 in San Diego, CA.

• 

  Sana Downsizes Staff by 29%, Refocuses on Ex Vivo Cell Therapy Platform

  10/11/2023

  The biotech is laying off about 29% of its employees and will focus its resources on the company’s hypoimmune platform. The latest downsizing follows a previous round of layoffs in August 2023.

• Sana Biotechnology Announces Increased Focus on Hypoimmune-Related Pipeline with the Potential to Deliver Clinical Proof of Concept Data from Four Programs in 2023 and 2024 with a 2024 Operating Burn under $200M

  10/10/2023

  Sana Biotechnology, Inc., a company focused on changing the possible for patients through engineered cells, announced a portfolio update, including both increased focus on its ex vivo cell therapy product candidates and an IND submission for SC291 in autoimmune diseases.

• Sana Biotechnology to Present at September 2023 Investor Conferences

  8/30/2023

  Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at five investor conferences in September.

• Sana Biotechnology Reports Second Quarter 2023 Financial Results and Business Updates

  8/3/2023

  Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today reported financial results and business highlights for the second quarter 2023.

• 

  Sana Biotechnology Advances R&D Platform to Overcome Immune Rejection

  7/31/2023

  With its hypoimmune technology, the company looks to reshape the future of cell and gene therapy.

• Sana Biotechnology Highlights Preclinical Data from Hypoimmune and Fusogen Platforms at the International Society for Stem Cell Research (ISSCR) 2023 Annual Meeting

  6/16/2023

  Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced preclinical data from six presentations, including two oral presentations, at the International Society for Stem Cell Research (ISSCR) 2023 Annual Meeting.

• Sana Biotechnology to Present at June 2023 Investor Conferences

  5/31/2023

  Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in June.

• Sana Biotechnology Reports First Quarter 2023 Financial Results and Business Updates

  5/8/2023

  Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today reported financial results and business highlights for the first quarter 2023.

• Sana Biotechnology Announces Preclinical Data Published in Nature Biotechnology Demonstrating its Hypoimmune-Engineered Cells Escape Immune Detection and Survive While Remaining Fully Functional

  5/8/2023

  Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that Nature Biotechnology has published a paper titled “Hypoimmune induced pluripotent stem cells survive long term in fully immunocompetent, allogeneic rhesus macaques.”

• Sana Biotechnology to Present at May 2023 Investor Conferences

  5/3/2023

  Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in May.

• Sana Biotechnology Announces the Acceptance of Six Abstracts for Presentation at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting

  5/2/2023

  Sana Biotechnology, Inc. (NASDAQ: SANA) today announced that six abstracts highlighting preclinical data from the fusogen platform have been accepted for presentation, including two oral presentations, at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting taking place May 16-20, 2023 in Los Angeles, CA.

• Sana Biotechnology to Host Research & Development Day

  4/24/2023

  Sana Biotechnology, Inc., a company focused on changing the possible for patients through engineered cells, announced that management will host a Research & Development Day on Thursday, May 23, 2023 from 9:00 a.m. – 12:00 p.m. ET in New York, NY.

• Sana Biotechnology Highlights Preclinical Hypoimmune Data for its Allogeneic CAR T Platform and Advancements with its In Vivo Fusogen Platform with Four Presentations at the 2023 AACR Annual Meeting

  4/19/2023

  Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced data from four presentations at the 2023 American Association for Cancer Research (AACR) Annual Meeting.

• Sana Biotechnology Announces Preclinical Data Published in Nature Communications Demonstrating the Ability of its Hypoimmune Allogeneic CD19-directed CAR T Cells to Evade Immune Rejection and Produce Durable Anti-Tumor Responses

  4/13/2023

  Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that Nature Communications has published a paper titled “Hypoimmune anti-CD19 chimeric antigen receptor T cells provide lasting tumor control in fully immunocompetent allogeneic humanized mice.”